Our Therapeutic Focus
Persica is developing a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic changes. PP353 is being developed to be the first approved pharmaceutical treatment for cLBP with Modic changes. Modic changes are associated with cLBP and caused by a bacterial infection in vertebral discs. Research by Persica’s founders demonstrated that high-dose oral antibiotics delivered over 100 days showed significant reduction of pain.
PP353
PP353 is a patented, targeted intradiscal antibiotic injection that is delivered directly to the site of infection. It is designed to achieve superior antibiotic disc exposure, with a one-off treatment, thereby reducing systemic side-effects, improving patient compliance and antibiotic stewardship.
PP353 is a non-opioid treatment which addresses an underlying cause, rather than just the symptoms, of cLBP.
Targeting a Significant Unmet Need
cLBP is highly debilitating and affects the quality of life of millions of people, with existing treatments targeting symptoms rather than underlying pathology. The lack of effective treatment options for patients often results in long-term reliance on analgesics, including opioids, to manage pain. The target population for PP353 encompasses approximately 2 million patients in the US alone, identifiable by MRI.